GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) (“GoodRx” or the “Company”) on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the “Class Period”). This action, captioned Barsuli v. GoodRx Holdings, Inc., et al., Case No. Case 2:24-cv-03282 was filed in th.

GDRX INVESTOR ALERT: Kessler Topaz Meltzer & Check, LLP Files A Securities Fraud Class Action Lawsuit Against GoodRX Holdings, Inc. And Encourages Investors With Losses To Contact The Firm

Altimmune

Eli Lilly

Novo Nordisk

Viking Therapeutics

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Here is how GoodRx Holdings, Inc. (GDRX) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.

Is GoodRx (GDRX) Outperforming Other Medical Stocks This Year?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., today announced it will release its first quarter 2024 financial results before U.S. markets open on Thursday, May 9, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conferen.

GoodRx Announces Date for First Quarter 2024 Earnings Release and Conference Call

GoodRx Holdings Inc (NASDAQ:GDRX) stock is up 1.9% to trade at $6.87 this morning, after Keybanc upgraded the digital healthcare service to "overweight" from "sector weight," while setting a price target of $9.

GoodRx Stock Upgraded on Growth Potential

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, the leading destination for prescription savings in the U.S., today announced that Publix has joined the GoodRx Gold network. Members now have access to prescription savings of up to 90%1 at more than 1,200 Publix pharmacy locations across the Southeast. GoodRx Gold is a monthly healthcare membership that gives consumers access to discounted prices on their medications, with more than 1,000 popular prescriptions priced at less than $10. In addition.

GoodRx Adds Publix to GoodRx Gold Network

GoodRx got an upgrade from Wells Fargo. The analysts appreciate the company's increased-revenue visibility.

Why GoodRx Surged Today

Elevance Health Inc

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or GoodRx Holdings, Inc. (GDRX). But which of these two stocks presents investors with the better value opportunity right now?

ELV or GDRX: Which Is the Better Value Stock Right Now?

The consensus price target hints at a 29.1% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 29.1% Upside in GoodRx Holdings, Inc. (GDRX): Here's What You Should Know

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced Interim CEO Scott Wagner has extended his commitment to the Company. In addition, Stephen LeSieur and Adam Karol have notified GoodRx of their decision to resign from the Company's Board of Directors, effective March 14, 2024 and March 22, 2024, respectively. “I'm encouraged by the progress the team is making and happy to see the hard work st.

GoodRx Interim CEO Extends Commitment to Company

GoodRx Holdings, Inc. (GDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can GoodRx Holdings, Inc. (GDRX) Run Higher on Rising Earnings Estimates?

Does GoodRx Holdings, Inc. (GDRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

GoodRx Holdings, Inc. (GDRX) is a Great Momentum Stock: Should You Buy?

While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GoodRx Holdings, Inc. (GDRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx beat Q4 estimates and announced a new $450 million stock repurchase program. The prescription savings specialist also issued better-than-expected 2024 revenue guidance.

Why GoodRx Stock Soared Today

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2023 Earnings Conference Call February 29, 2024 8:00 AM ET

GoodRx Holdings, Inc. (GDRX) Q4 2023 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago.

GoodRx Holdings, Inc. (GDRX) Matches Q4 Earnings Estimates

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the fourth quarter and full year 2023, which are consistent with its preliminary results announced on January 10, 2024. Fourth Quarter 2023 Highlights Revenue1 and Adjusted Revenue1,2 of $196.6 million Net loss of $25.9 million; Net loss margin of 13.2% Adjusted Net Income2 of $31.1 million;.

GoodRx Reports Fourth Quarter and Full Year 2023 Results

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for GoodRx Holdings, Inc. (GDRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Countdown to GoodRx Holdings, Inc. (GDRX) Q4 Earnings: Wall Street Forecasts for Key Metrics

GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GoodRx Holdings, Inc. (GDRX) Reports Next Week: What Awaits?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, the leading destination for prescription savings in the U.S., today announced it is offering 30 of the most common heart health medications for under $30 at more than 70,000 pharmacies nationwide.1 Cardiovascular disease is one of the most prominent conditions facing Americans, affecting nearly half of all U.S. adults. That's why GoodRx is making it easier for all individuals, regardless of insurance status, to access savings on both generic and br.

GoodRx Now Offering 30 Common Heart Health Medications for Under $30

bluebird bio

CRISPR Therapeutics

Gilead Sciences

Sarepta Therapeutics

Vertex Pharmaceuticals

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.

Gene therapy: Why does it cost millions for a single treatment?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S, today announced it will release its fourth quarter and full year 2023 financial results before U.S. markets open on Thursday, February 29, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To.

GoodRx Announces Date for Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

The consensus price target hints at a 27.8% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in GoodRx Holdings, Inc. (GDRX)? Wall Street Analysts Think 27.83%

During flu season, you want to be on top of your strategy on how to quickly get better if you're sick. Each month, PYMNTS tracks the most popular mobile apps in the prescription space for the Provider Ranking of Prescription Apps.

GoodRx Leads Provider Ranking of Prescription Apps for Sixth Straight Month

GoodRx has a strong value proposition that drives continuous adoption, offering cost savings and price comparisons on medications. The company benefits from a strong network effect, with consumers, PBMs, and pharmacies incentivized to join the network, leading to increased volume and market share. While growth may be weak in the short term, the company has potential for margin expansion and is positioned for long-term success.

News for GoodRx Holdings Stock (GDRX)